ЛИТЕРАТУРА

Ведение женщин в пери- и постменопаузе: практические рекомендации/Под ред. В.П.Сметник, Л.М.Ильиной. - М.: Ярославль: ООО "ИПК "Литера", 2010.-221 с.

Santen P.J., Allred D.C., Androin S.P., et al. Postmenopausal hormone therapy: an Endocrine Society Scientific Statement//J. Clin. Endocrinol. Metab. 2010; 95 (Suppl. 1): 1-66.

Sturdee D.W., Panay N. (Writing Group) Recommendations for the management of postmenopausal vaginal atrophy//J. Climacteric 2010; 13: 509-522.

Sturdee D.W., Pines A., Archer D.F., Baber D.F. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health//J. Climacteric 2011; 14: 302-320.

Liao S., Li J., Wei W., et al. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature//Asian Рас. J. Cancer Prev. 2011; 12: 1061-1065.

Rees M., Peres-Lopez F.R., Ceasu I., et al. EMAS clinical guide: low-dose vaginal estrogen for postmenopausal vaginal atrophy//Maturitas 2012; 73: 171-174.

The North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause 2012; 19:257-271.

Cagnacci A., Cannoletta M., Palma F., et al. Menopausal symptoms and risk factors for cardiovascular disease in postmenopause//J. Climacteric. 2012; 15: 157-162.

Harlow S.D., Gass M., Hall J.H. et al. Executive Summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging//J. Climacteric. 2012; 15: 105-114.

De Villiers T.J., Pines A., Panay N., et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health//J. Climacteric. 2013; 16: 316-337.

Position Statement Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society//J. Menopause. 2013; 20 (9): 888-902.

Pickar J.H. Emerging therapies for postmenopausal vaginal atrophy//Maturitas. 2013; 75: 3-6.

Panay N., Hamoda H., Arya R. et al. The 2013 British Menopause Society, Women Health Concern recommendation on hormone replacement therapy//Menopause Int. 2013; 19(2): 59-68.

Genazzani A.R., Schmelter Т., Schaefers M. et al. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17-estradiol in postmenopausal women//Climacteric. 2013; 16: 490-8.

De Villiers T.J., Gass M.L., Haines C.J. et al. Global Consensus Statement on Menopausal Hormone Therapy//Climacteric. 2013; 16: 203 - 4.

Matsui S., Yasui Т., Tani A. et al. Effect of ultra-low-dose estradiol and dydrogesterone on arterial stiffness in postmenopausal women//J. Climacteric. 2014; 17: 191-6.

Archer D.F., Schmelter Th., Schaefers M. et al. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17-estradiol for moderate to severe vasomotor symptoms in postmenopausal women//Menopause. 2014; 21(3): 227-235.

Practice Bulletin No. 141: Management of Menopausal Symptoms//Obstet. Gynecol. 2014; 123: 202-216.

Wierman M.E., Arit W., Basson R. et al. Androgen therapy in women: a reappraisal: an Endocrine Society Clinical Practice Guideline//J. Clin. Endocrinol. Metab. 2014; 95: 3489-3510.

Shifren J.L., Gass M.L.S. and Working Group. Recommendations for clinical care of midlife women (The N orth American Menopause Society)//J. Menopause. 2014; 21 (10): 1038-1062.

Portman D.J., Gass M.L.S. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society//J. Menopause. 2014; 21 (10): 1063-1068.